Sarcoma classification: An update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone

Cancer

Volumn 120, Issue 12, 2014, Pages 1763-1774

  Doyle, Leona A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

bone; sarcoma; soft tissue; tumor; tumor classification; World Health Organization

Indexed keywords

ADIPOSE TISSUE; BONE TUMOR; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CHONDROSARCOMA; CHORDOMA; DISEASE ASSOCIATION; FIBROHISTIOCYTOMA; FIBROSARCOMA; GENE MUTATION; GIANT CELL TUMOR; HUMAN; LIPOSARCOMA; MYOSARCOMA; NERVE SHEATH TUMOR; ONCOGENE; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; SARCOMA; SOFT TISSUE TUMOR; STOMACH SARCOMA; UNDIFFERENTIATED CARCINOMA; VASCULAR TUMOR; WORLD HEALTH ORGANIZATION;

BONE; SARCOMA; SOFT TISSUE; TUMOR; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION;

BONE NEOPLASMS; HUMANS; SARCOMA; SOFT TISSUE NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 84902140372     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28657     Document Type: Review

References (73)

1. Fletcher CD, Hogendoorn P, Mertens F, Bridge J,. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press; 2013.
2. Fletcher CDM, Unni KK, Mertens F,. WHO Classification of Tumours of Soft Tissue and Bone. 3rd ed. Lyon, France: IARC Press; 2002.
3. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001; 7: 3977-3987.
4. Haniball J, Sumathi VP, Kindblom LG, et al. Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma. Sarcoma. 2011;2011: 538085.
5. Moreau LC, Turcotte R, Ferguson P, et al. Myxoid/round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases. Ann Surg Oncol. 2012; 19: 1081-1088.
6. Boland JM, Weiss SW, Oliveira AM, Erickson-Johnson ML, Folpe AL,. Liposarcomas with mixed well-differentiated and pleomorphic features: a clinicopathologic study of 12 cases. Am J Surg Pathol. 2010; 34: 837-843.
7. Marino-Enriquez A, Fletcher CD, Dal Cin P, Hornick JL,. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria. Am J Surg Pathol. 2010; 34: 1122-1131.
8. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013; 45: 180-185.
9. Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013; 45: 131-132.
10. Mohajeri A, Tayebwa J, Collin A, et al. Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer. 2013; 52: 873-886.
11. Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013; 125: 651-658.
12. Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL,. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014; 27: 390-395.
13. Guillou L, Benhattar J, Gengler C, et al. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am J Surg Pathol. 2007; 31: 1387-1402.
14. Rekhi B, Folpe AL, Deshmukh M, Jambhekar NA,. Sclerosing epithelioid fibrosarcoma-a report of two cases with cytogenetic analysis of FUS gene rearrangement by FISH technique. Pathol Oncol Res. 2011; 17: 145-148.
15. Doyle LA, Wang WL, Dal Cin P, et al. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am J Surg Pathol. 2012; 36: 1444-1451.
16. Lau PP, Lui PC, Lau GT, Yau DT, Cheung ET, Chan JK,. EWSR1-CREB3L1 gene fusion: a novel alternative molecular aberration of low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2013; 37: 734-738.
17. Doyle LA, Hornick JL,. EWSR1 rearrangements in sclerosing epithelioid fibrosarcoma. Am J Surg Pathol. 2013; 37: 1630-1631.
18. Arbajian E, Puls F, Magnusson L, et al. Recurrent EWSR1-CREB3L1 gene fusions in sclerosing epithelioid fibrosarcoma [published online ahead of print January 16, 2014]. Am J Surg Pathol.
19. Doyle LA, Moller E, Dal Cin P, Fletcher CD, Mertens F, Hornick JL,. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol. 2011; 35: 733-741.
20. Moller E, Hornick JL, Magnusson L, Veerla S, Domanski HA, Mertens F,. FUS-CREB3L2/L1-positive sarcomas show a specific gene expression profile with upregulation of CD24 and FOXL1. Clin Cancer Res. 2011; 17: 2646-2656.
21. Erickson-Johnson MR, Chou MM, Evers BR, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 2011; 91: 1427-1433.
22. Nascimento AF, Fletcher CD,. Spindle cell rhabdomyosarcoma in adults. Am J Surg Pathol. 2005; 29: 1106-1113.
23. Mentzel T,. Spindle cell rhabdomyosarcoma in adults: a new entity in the spectrum of malignant mesenchymal tumors of soft tissues [in German]. Pathologe. 2010; 31: 91-96.
24. Mentzel T, Kuhnen C,. Spindle cell rhabdomyosarcoma in adults: clinicopathological and immunohistochemical analysis of seven new cases. Virchows Arch. 2006; 449: 554-560.
25. Mosquera JM, Sboner A, Zhang L, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013; 52: 538-550.
26. Szuhai K, de Jong D, Leung WY, Fletcher CD, Hogendoorn PC,. Transactivating mutation of the MYOD1 gene is a frequent event in adult spindle cell rhabdomyosarcoma. J Pathol. 2014; 232: 300-307.
27. Hornick JL, Fletcher CD,. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol. 2011; 35: 190-201.
28. Billings SD, Folpe AL, Weiss SW,. Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol. 2003; 27: 48-57.
29. Walther C, Tayebwa J, Lilljebjorn H, et al. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic hemangioendothelioma [published online ahead of print December 28, 2013]. J Pathol. doi: 10.1002/path. 4322.
30. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011; 50: 644-653.
31. Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011; 3: 98ra82.
32. Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013; 52: 775-784.
33. Errani C, Sung YS, Zhang L, Healey JH, Antonescu CR,. Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. Cancer Genet. 2012; 205: 12-17.
34. Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR,. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer. 2011; 50: 25-33.
35. Mentzel T, Schildhaus HU, Palmedo G, Buttner R, Kutzner H,. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol. 2012; 25: 75-85.
36. Gill AJ, Chou A, Vilain RE, Clifton-Bligh RJ,. "Pediatric-type" gastrointestinal stromal tumors are SDHB negative ("type 2") GISTs. Am J Surg Pathol. 2011; 35: 1245-1247; author reply 1247-1248.
37. Rege TA, Wagner AJ, Corless CL, Heinrich MC, Hornick JL,. "Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior. Am J Surg Pathol. 2011; 35: 495-504.
38. Doyle LA, Nelson D, Heinrich MC, Corless CL, Hornick JL,. Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology. 2012; 61: 801-809.
39. Wagner AJ, Remillard SP, Zhang YX, Doyle LA, George S, Hornick JL,. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. Mod Pathol. 2013; 26: 289-294.
40. Oudijk L, Gaal J, Korpershoek E, et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod Pathol. 2013; 26: 456-463.
41. Miettinen M, Killian JK, Wang ZF, et al. Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation. Am J Surg Pathol. 2013; 37: 234-240.
42. Dwight T, Benn DE, Clarkson A, et al. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol. 2013; 37: 226-233.
43. Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J,. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011; 35: 1712-1721.
44. Zhang L, Smyrk TC, Young WF Jr, Stratakis CA, Carney JA,. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol. 2010; 34: 53-64.
45. Marrari A, Wagner AJ, Hornick JL,. Predictors of response to targeted therapies for gastrointestinal stromal tumors. Arch Pathol Lab Med. 2012; 136: 483-489.
46. Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008; 14: 3204-3215.
47. Browne TJ, Fletcher CD,. Haemosiderotic fibrolipomatous tumour (so-called haemosiderotic fibrohistiocytic lipomatous tumour): analysis of 13 new cases in support of a distinct entity. Histopathology. 2006; 48: 453-461.
48. Marshall-Taylor C, Fanburg-Smith JC,. Hemosiderotic fibrohistiocytic lipomatous lesion: ten cases of a previously undescribed fatty lesion of the foot/ankle. Mod Pathol. 2000; 13: 1192-1199.
49. Wettach GR, Boyd LJ, Lawce HJ, Magenis RE, Mansoor A,. Cytogenetic analysis of a hemosiderotic fibrolipomatous tumor. Cancer Genet Cytogenet. 2008; 182: 140-143.
50. Antonescu CR, Zhang L, Nielsen GP, Rosenberg AE, Dal Cin P, Fletcher CD,. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer. 2011; 50: 757-764.
51. Elco CP, Marino-Enriquez A, Abraham JA, Dal Cin P, Hornick JL,. Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: report of a case providing further evidence for a pathogenetic link. Am J Surg Pathol. 2010; 34: 1723-1727.
52. Bahrami A, Weiss SW, Montgomery E, et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumors with and without known tumor induced osteomalacia. Am J Surg Pathol. 2009; 33: 1348-1354.
53. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia- associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004; 28: 1-30.
54. Fletcher CD,. Undifferentiated sarcomas: what to do? And does it matter? A surgical pathology perspective. Ultrastruct Pathol. 2008; 32: 31-36.
55. Choi EY, Thomas DG, McHugh JB, et al. Undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: a novel highly aggressive soft tissue tumor with distinctive histopathology. Am J Surg Pathol. 2013; 37: 1379-1386.
56. Graham C, Chilton-MacNeill S, Zielenska M, Somers GR,. The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. Hum Pathol. 2012; 43: 180-189.
57. Italiano A, Sung YS, Zhang L, et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer. 2012; 51: 207-218.
58. Kawamura-Saito M, Yamazaki Y, Kaneko K, et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet. 2006; 15: 2125-2137.
59. Machado I, Cruz J, Lavernia J, et al. Superficial EWSR1-negative undifferentiated small round cell sarcoma with CIC/DUX4 gene fusion: a new variant of Ewing-like tumors with locoregional lymph node metastasis. Virchows Arch. 2013; 463: 837-842.
60. Yoshimoto M, Graham C, Chilton-MacNeill S, et al. Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event. Cancer Genet Cytogenet. 2009; 195: 1-11.
61. Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet. 2012; 44: 461-466.
62. Carney JA, Boccon-Gibod L, Jarka DE, et al. Osteochondromyxoma of bone: a congenital tumor associated with lentigines and other unusual disorders. Am J Surg Pathol. 2001; 25: 164-176.
63. Evans HL, Ayala AG, Romsdahl MM,. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977; 40: 818-831.
64. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008; 13: 320-329.
65. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011; 224: 334-343.
66. Damato S, Alorjani M, Bonar F, et al. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology. 2012; 60: 363-365.
67. Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011; 43: 1262-1265.
68. Wang L, Motoi T, Khanin R, et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer. 2012; 51: 127-139.
69. Yoshida A, Ushiku T, Motoi T, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010; 23: 1279-1288.
70. Mejia-Guerrero S, Quejada M, Gokgoz N, et al. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer. 2010; 49: 518-525.
71. Romeo S, Bovee JV, Kroon HM, et al. Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. Virchows Arch. 2012; 461: 561-570.
72. Nielsen GP, Srivastava A, Kattapuram S, et al. Epithelioid hemangioma of bone revisited: a study of 50 cases. Am J Surg Pathol. 2009; 33: 270-277.
73. Jeon DG, Song WS, Kong CB, Kim JR, Lee SY,. MFH of bone and osteosarcoma show similar survival and chemosensitivity. Clin Orthop Relat Res. 2011; 469: 584-590.